TC BioPharm Limited Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Basic and diluted loss per share (Tables)

Basic and diluted loss per share (Tables)

12 Months Ended

Dec. 31, 2022

Summary of basic and diluted earnings per share

	Year ended December 31,			Year ended December 31,			Year ended December 31,
	2022			2021			2020
	£			£			£
Loss for the year		(1,389,706	)		(13,575,925	)	(5,457,916	)
Basic and diluted weighted average number of shares outstanding⁽¹⁾		687,199			390,585		378,481

Basic and diluted loss per share		(2.02	)		(34.76	)	(14.42	)

(1)

On November 18, 2022, TC BioPharm (Holdings) plc completed a reverse stock split of one (1) new share for every fifty (50) existing shares effective November 21, 2022. As a result of the share split, all references in these financial statements and accompanying notes to units of ordinary shares or per share amounts are reflective of the reverse share split for all periods presented. In addition, the exercise prices and the numbers of ordinary shares issuable upon the exercise of any outstanding options to purchase ordinary shares were proportionally adjusted pursuant to the respective anti-dilution terms of the share-based payment plans.